Evidence map›Paper›PMID 41323518›Full record

ArticleInflammatory intestinal diseases

Evolution of Growth following Anti-Tumor Necrosis Factor-α Therapy in Paediatric Crohn's Disease: Data from the Swiss IBD Cohort Study.

Cléa Kunz, Alain Schoepfer, Christiane Sokollik, Mathilde Crédeville, Vasikili Spyropoulou, Franziska Righini Grunder, Michela G Schaeppi Tempia, Henrik Köhler, Andreas Nydegger, Swiss IBD Cohort Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Cléa KunzPaediatric Gastroenterology Unit of University Hospital of Vaud (CHUV), Lausanne, Switzerland.
Alain SchoepferGastroenterology Department of CHUV, Lausanne, Switzerland.
Christiane SokollikDivision of Paediatric Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Inselspital, University of Bern, Bern, Switzerland.
Mathilde CrédevillePaediatric Gastroenterology Unit of Geneva General Hospitals (HUG), Geneva, Switzerland.
Vasikili SpyropoulouPaediatric Gastroenterology and Hepatology of the Children's Hospital in Zürich (KISPI), Zurich, Switzerland.
Franziska Righini GrunderPaediatric Gastroenterology, Hepatology and Nutrition Unit of the Children's Hospital of Central Switzerland, Lucerne, Switzerland.
Michela G Schaeppi TempiaGrangettes Clinic in Geneva, Geneva, Switzerland.
Henrik KöhlerChildren's Hospital of Aarau, Aarau, Switzerland.
Andreas NydeggerPaediatric Gastroenterology Unit of University Hospital of Vaud (CHUV), Lausanne, Switzerland.
Swiss IBD Cohort Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Up to 85% of pediatric patients affected by Crohn's disease experience growth failure. This study aims to elucidate the effects of anti-tumor necrosis factor (TNF) biologics on patient growth. Methods: This retrospective analysis examined height, height velocity and weight in pediatric patients with Crohn's disease from the Swiss Inflammatory Bowel Disease Cohort Study between 2007 and 2020 ( Results: Mean height and weight z-scores at diagnosis were -0.3 ± 1.3 and -1.0 ± 1.6, respectively (age at diagnosis 11.1 ± 2.7 years, 52.0% male). Initial treatment was led by azathioprine (58.3%) and infliximab (19.8%). Patients treated with biologics exhibited significant height increase at T1 ( Conclusion: Our findings indicate that anti-TNF biologics are associated with significant short-term height and long-term weight gains in pediatric patients with Crohn's disease, similar to those observed with immunomodulators.

Indexed as

Crohn’s diseaseHeightImmunomodulatorsInfliximabWeight

Identifiers

PMID41323518
PMCPMC12659624

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.